RecruitingNot ApplicableNCT07464392

FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis

Fecal Microbiota Transplantation for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis: A Multicenter, Randomized, Double-Blind Clinical Trial


Sponsor

Changhai Hospital

Enrollment

150 participants

Start Date

Apr 2, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to learn whether fecal microbiota transplantation (FMT) works to prevent infections complications in patients in the late phase of moderately severe or severe acute pancreatitis.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria6

  • Age between 18 and 75 years
  • Diagnosed with moderately severe acute pancreatitis (MSAP) or severe acute pancreatitis (SAP) according to the Revised Atlanta Classification 2012, with CT severity index (CTSI) score > 4
  • Disease duration of 15 to 21 days
  • Already have a nasojejunal tube in place
  • No absolute contraindications to fecal microbiota transplantation
  • Voluntarily sign the written informed consent form

Exclusion Criteria11

  • Concurrent severe systemic infection
  • Concurrent extra-intestinal organ infection requiring intervention with broad-spectrum antibiotics
  • Intestinal obstruction, active gastrointestinal bleeding, intestinal perforation, fulminant colitis, or toxic megacolon
  • Unable to tolerate enteral nutrition meeting 50% of caloric requirements due to severe diarrhea, significant fibrotic intestinal stricture, severe gastrointestinal bleeding, or high-output intestinal fistula
  • Pre-existing chronic organ dysfunction (heart, lung, liver, kidney, or hematologic system) prior to admission
  • Multiple organ dysfunction syndrome (MODS) with a confirmed duration exceeding 2 weeks
  • Active malignancy
  • Autoimmune disease or immunocompromised status (including solid organ or bone marrow transplantation, AIDS, long-term use of immunosuppressants or hormones)
  • Congenital or acquired immunodeficiency
  • Pregnancy or breastfeeding
  • Severe mental disorder

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALFecal Microbiota Transplantation

Fecal microbiota transplantation (FMT) liquid is a biological intervention consisting of processed and standardized human fecal microbiota from healthy donors, suspended in sterile saline with cryoprotectant.

OTHERPlacebo

Sterile saline (0.9% sodium chloride) solution, packaged identically to FMT liquid with opaque materials to maintain blinding, contains no active components and serves as a placebo control.


Locations(12)

The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine

Fuzhou, Fujian, China

Quanzhou First Hospital, Fujian

Quanzhou, Fujian, China

Guangdong Hospital of Traditional Chinese Medicine

Guangzhou, Guangdong, China

Guangzhou Medical University Affiliated Panyu Central Hospital

Guangzhou, Guangdong, China

The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

The Affiliated Qingyuan People's Hospital of Guangzhou Medical University

Qingyuan, Guangdong, China

Affiliated Hospital of Guangdong Medical University

Zhanjiang, Guangdong, China

Changhai Hospital

Shanghai, Shanghai Municipality, China

Renji Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

Shanghai General Hospital

Shanghai, Shanghai Municipality, China

Shanghai Tenth People's Hospital ,Tenth People's Hospital Affiliated to Tongji University)

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07464392


Related Trials